Stability of amorphous indomethacin compounded with silica.

The stability of indomethacin (IM) compounded with SiO(2) either by co-grinding or by melt-quenching was examined by recrystallization kinetics under the conditions 30 degrees C and 11% relative humidity. A decrease of the recrystallization rate with and without an appreciable induction period was observed in both compounds. Higher stability of amorphous IM compounded with SiO(2) was attained by prolonged co-grinding than by melt-quenching. This was explained by the stronger chemical interaction at the interface between IM and SiO(2) by co-grinding, as revealed by (29)Si and (13)C solid state NMR. Incomplete co-grinding with the rest of the crystalline state, however, made the amorphous state appreciably unstable, since the remaining crystallites serve as seeds for recrystallization.

[1]  Bruno C. Hancock,et al.  Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates. , 1995, Journal of pharmaceutical sciences.

[2]  D. Grant,et al.  Solid‐state 13C NMR study of drugs: Aspirin , 1986 .

[3]  G. Zografi,et al.  Effects of sorbed water on the crystallization of indomethacin from the amorphous state. , 1997, Journal of pharmaceutical sciences.

[4]  Keiji. Yamamoto,et al.  Dissolution improvement of RS-8359 by the solid dispersion prepared by the solvent method , 1998 .

[5]  S. Georgieva,et al.  Aspects of the interactions between indomethacin and nicotinamide in solid dispersions , 1998 .

[6]  C. Nyström,et al.  Comparison of solid-state NMR and isothermal microcalorimetry in the assessment of the amorphous component of lactose , 1998 .

[7]  S. Lin.  Isolation and solid-state characteristics of a new crystal form of indomethacin. , 1992, Journal of pharmaceutical sciences.

[8]  T. Fukuchi.  Vacancy-associated type ESR centers observed in natural silica and their application to geology , 1993 .

[9]  N Kaneniwa,et al.  Effect of environmental temperature on polymorphic solid-state transformation of indomethacin during grinding. , 1986, Chemical & pharmaceutical bulletin.

[10]  Spectroscopic identification of an amorphous-to-crystalline drug transition in a solid dispersion SCH 48461 capsule formulation. , 1997, Journal of pharmaceutical and biomedical analysis.

[11]  D. Middleton,et al.  A cross-polarization magic-angle spinning 13C NMR characterization of the stable solid-state forms of cimetidine. , 1997, Journal of pharmaceutical sciences.

[12]  F. Hirayama,et al.  Characterization of tolbutamide polymorphs (Burger's forms II and IV) and polymorphic transition behavior. , 1999, Journal of pharmaceutical sciences.

[13]  Bruno C. Hancock,et al.  Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. , 1994, Journal of pharmaceutical sciences.

[14]  S. Hirota,et al.  Mechano-chemical formation of indomethacin β cyclodextrin inclusion compounds in powder phase roll mixtures , 1997 .

[15]  C. Cimpoiu,et al.  The control over the new obtaining procedeum of indomethacin. , 1998, Journal of pharmaceutical and biomedical analysis.

[16]  R. Brückner,et al.  Properties and structure of vitreous silica. I , 1970 .

[17]  T. Eguchi,et al.  Solid-State Characterization of Candesartan Cilexetil (TCV-116): Crystal Structure and Molecular Mobility , 1999 .

[18]  C. W. Price.  Use of Kolmogorov-Johnson-Mehl-Avrami kinetics in recrystallization of metals and crystallization of metallic glasses , 1990 .

[19]  L. Facchini,et al.  Silicon-29 NMR study of silica , 1992 .

[20]  D. A. Williams,et al.  Solid-state β-cyclodextrin complexes containing indomethacin, ammonia and water. I. Formation studies , 1998 .

[21]  M. Vachon,et al.  The use of 13C solid state NMR to elucidate physico-chemical association in Eudragit RS100 microencapsulated acyl esters of salicylic acid. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[22]  D. Law,et al.  Nucleation and crystallization kinetics of hydrated amorphous lactose above the glass transition temperature. , 1999, Journal of pharmaceutical sciences.